About this source
- Kind
- Regulatory or official document
- Population
- Not applicable (regulatory assessment); underlying trial population per the pivotal NEJM trial
- Primary or secondary
- primary
- Peer review
- unknown
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
The application was withdrawn by the applicant before a final CHMP opinion was reached, a provisional/preliminary CHMP assessment (data did not allow the Committee to conclude on a positive benefit-risk balance), not a formal refusal.
Cited in
EMA IGF-1 elevation concern
Tesamorelin · Safety finding
UK regulatory status
Tesamorelin · UK regulatory status
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.